PL2635604T3 - Kompozycja przeciwciała PAN-HER - Google Patents

Kompozycja przeciwciała PAN-HER

Info

Publication number
PL2635604T3
PL2635604T3 PL11797354T PL11797354T PL2635604T3 PL 2635604 T3 PL2635604 T3 PL 2635604T3 PL 11797354 T PL11797354 T PL 11797354T PL 11797354 T PL11797354 T PL 11797354T PL 2635604 T3 PL2635604 T3 PL 2635604T3
Authority
PL
Poland
Prior art keywords
pan
antibody composition
antibody
composition
Prior art date
Application number
PL11797354T
Other languages
English (en)
Polish (pl)
Inventor
Mikkel Wandahl Pedersen
Ida K. Christensen
Johan Lantto
Helle Jacobsen
Michael Kragh
Original Assignee
Symphogen A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen A/S filed Critical Symphogen A/S
Publication of PL2635604T3 publication Critical patent/PL2635604T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11797354T 2010-11-01 2011-10-31 Kompozycja przeciwciała PAN-HER PL2635604T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06

Publications (1)

Publication Number Publication Date
PL2635604T3 true PL2635604T3 (pl) 2017-09-29

Family

ID=59014867

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11797354T PL2635604T3 (pl) 2010-11-01 2011-10-31 Kompozycja przeciwciała PAN-HER

Country Status (13)

Country Link
US (1) US9217039B2 (enExample)
EP (3) EP2635605B1 (enExample)
JP (2) JP6186277B2 (enExample)
KR (2) KR101862832B1 (enExample)
AU (2) AU2011324871B2 (enExample)
CA (2) CA2816519C (enExample)
DK (1) DK2635604T3 (enExample)
ES (2) ES2616961T3 (enExample)
IL (2) IL225954B (enExample)
MX (2) MX347981B (enExample)
PL (1) PL2635604T3 (enExample)
TW (1) TW201231066A (enExample)
WO (2) WO2012059858A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638579T3 (es) * 2008-08-29 2017-10-23 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
WO2010029534A1 (en) 2008-09-15 2010-03-18 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
JP2014509593A (ja) * 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ＥｒｂＢ経路阻害剤に対する耐性の克服
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
CA2952347A1 (en) * 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
JP6180425B2 (ja) 2011-11-23 2017-08-23 メディミューン，エルエルシー Ｈｅｒ３に特異的な結合分子及びそれらの使用
CA2865082A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
EP2844675B1 (en) 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EA036902B1 (ru) * 2013-09-20 2021-01-13 Бристол-Майерс Сквибб Компани Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CA2961323C (en) 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
PT3631454T (pt) 2017-05-30 2023-11-23 Bristol Myers Squibb Co Tratamento de tumores positivos para lag-3
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
KR102846109B1 (ko) 2018-09-07 2025-08-18 화이자 인코포레이티드 항-αvβ8 항체 및 그의 조성물 및 용도
JP2022520649A (ja) * 2019-02-14 2022-03-31 メルス ナムローゼ フェンノートシャップ Ｅｇｆｒ、ｈｅｒ２及びｈｅｒ３に結合する結合部分の組み合わせ
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022144836A1 (en) 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
AU2023274452A1 (en) 2022-05-27 2025-01-16 Innate Pharma Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
AR132710A1 (es) 2023-05-19 2025-07-23 Servier Lab Anticuerpos anti-met, adc, composiciones y usos de los mismos

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ331360A (en) 1996-03-27 2000-03-27 Genentech Inc an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
JPWO2004087763A1 (ja) * 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
BRPI0513714A (pt) 2004-07-20 2008-05-13 Symphogen As procedimento para caracterização estrutural de uma proteìna policlonal recombinante ou uma linhagem de célula policlonal
KR20150140417A (ko) 2004-07-22 2015-12-15 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
BRPI0518086A (pt) 2004-12-07 2008-10-28 Genentech Inc métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
CA2678181C (en) * 2007-02-16 2016-12-13 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
ES2582386T3 (es) * 2007-03-01 2016-09-12 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
DE602008002593D1 (de) 2007-05-25 2010-10-28 Symphogen As Verfahren zur herstellung eines rekombinanten polyklonalen proteins
WO2009065414A1 (en) 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
KR20110016899A (ko) 2008-04-23 2011-02-18 심포젠 에이/에스 폴리클로날 단백질을 제조하는 방법
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
ES2638579T3 (es) * 2008-08-29 2017-10-23 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
EP2335068A4 (en) 2008-10-06 2012-07-25 Symphogen As METHOD FOR IDENTIFYING AND SELECTING CANDIDATES MEDICINES FOR COMBINATORIAL DRUG PRODUCTS
MA33198B1 (fr) * 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
PE20120550A1 (es) 2009-04-07 2012-05-21 Roche Glycart Ag ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
CA2766608C (en) * 2009-07-06 2018-06-19 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
CN103002912A (zh) * 2009-08-21 2013-03-27 梅里麦克制药股份有限公司 针对ErbB3的胞外结构域的抗体及其用途
US20120195831A1 (en) 2009-10-09 2012-08-02 Ningyan Zhang Generation, characterization and uses thereof of anti-her3 antibodies
AU2010319483B2 (en) 2009-11-13 2015-03-12 Amgen Inc. Material and methods for treating or preventing HER-3 associated diseases
TW201141519A (en) 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
RU2568051C2 (ru) 2010-04-09 2015-11-10 Авео Фармасьютикалз, Инк. АНТИТЕЛА К ErbB3
ES2620255T3 (es) 2010-08-20 2017-06-28 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (HER3)
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.

Also Published As

Publication number Publication date
WO2012059857A2 (en) 2012-05-10
EP2635605A1 (en) 2013-09-11
JP6186277B2 (ja) 2017-08-23
IL225954B (en) 2018-05-31
DK2635604T3 (en) 2017-02-27
KR101773120B1 (ko) 2017-08-30
JP2014503188A (ja) 2014-02-13
KR20140026336A (ko) 2014-03-05
JP6033783B2 (ja) 2016-11-30
MX2013004899A (es) 2013-07-15
CA2816519C (en) 2019-01-15
KR101862832B1 (ko) 2018-05-30
EP2635605B1 (en) 2018-07-25
EP2635605A4 (en) 2014-10-22
AU2011324870B2 (en) 2015-01-29
MX348637B (es) 2017-06-22
CA2816520C (en) 2017-11-21
KR20140026337A (ko) 2014-03-05
EP3156421A1 (en) 2017-04-19
AU2011324871B2 (en) 2016-05-19
AU2011324870A1 (en) 2013-01-31
CA2816519A1 (en) 2012-05-10
US20130287684A1 (en) 2013-10-31
IL225953A0 (en) 2013-07-31
TW201231066A (en) 2012-08-01
EP3156421B1 (en) 2018-06-06
US9217039B2 (en) 2015-12-22
WO2012059857A3 (en) 2012-07-19
JP2014503189A (ja) 2014-02-13
AU2011324871A1 (en) 2013-05-09
MX347981B (es) 2017-05-22
ES2616961T3 (es) 2017-06-14
IL225954A0 (en) 2013-07-31
EP2635604B1 (en) 2016-11-30
WO2012059858A1 (en) 2012-05-10
CA2816520A1 (en) 2012-05-10
ES2692379T3 (es) 2018-12-03
MX2013004897A (es) 2013-07-15
EP2635604A2 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
IL225953A0 (en) An antidote–her@@pan
HUS1900020I1 (hu) CGRP ellenanyagok
PL2581113T3 (pl) Przeciwciało anty-tim-3
PT3342786T (pt) Anticorpo anti-dll3
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
DK3904391T3 (en) Monoclonal antibodies against c-met
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL223366B (en) antibody against cmet
IL221371A0 (en) Anti-lrp6 antibodies
IL226113A0 (en) combinations of met–c antibodies
IL222374A (en) Antiviral cleanser
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
SI2636736T1 (sl) Novo anti-dr5 protitelesce
GB201020738D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201002238D0 (en) Antibodies
EP2588141A4 (en) ANTIBODY FORMULATIONS
ZA201300804B (en) Anti-vegfr-3 antibody compositions
GB201007957D0 (en) Antibody
GB201017780D0 (en) Antibody
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies